Lakefront Biotherapeutics (GLPGF) Gross Profit Growth (1y) (2022 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Gross Profit Growth (1y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 17.43% |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | 11.52% |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 11.24% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 15.59% |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | 63.51% |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 126.09% |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 57.16% |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | -3.99% |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -94.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -94.89% |
| Mar 31, 2026 | -96.94% |
| Dec 31, 2025 | -87,750.48% |
| Sep 30, 2025 | -56.00% |
| Jun 30, 2025 | 359.26% |
| Mar 31, 2025 | -0.97% |
| Dec 31, 2024 | -93.24% |
| Sep 30, 2024 | 165.18% |
| Jun 30, 2024 | -143.58% |
| Mar 31, 2024 | 10.20% |
| Dec 31, 2023 | 420.43% |
| Sep 30, 2023 | -55.24% |
| Jun 30, 2023 | -57.84% |
| Mar 31, 2023 | -60.58% |
| Dec 31, 2022 | -82.77% |
| Sep 30, 2022 | -63.96% |
| Jun 30, 2022 | -14.34% |
| Mar 31, 2022 | 9.05% |